scholarly journals Adding serial N-terminal pro brain natriuretic peptide measurements to optimal clinical management in outpatients with systolic heart failure: a multicentre randomized clinical trial (NorthStar monitoring study)

2013 ◽  
Vol 15 (7) ◽  
pp. 818-827 ◽  
Author(s):  
Morten Schou ◽  
Finn Gustafsson ◽  
Lars Videbaek ◽  
Helge Andersen ◽  
Jens Toft ◽  
...  
Keyword(s):  
Heart Failure ◽  
Clinical Trial ◽  
Brain Natriuretic Peptide ◽  
Randomized Clinical Trial ◽  
Natriuretic Peptide ◽  
Clinical Management ◽  
Systolic Heart Failure ◽  
Monitoring Study

scholarly journals Diagnostic, Prognostic, and Therapeutic Value of Circulating miRNAs in Heart Failure Patients Associated with Oxidative Stress

2016 ◽  
Vol 2016 ◽  
pp. 1-13 ◽  
Author(s):  
Md Sayed Ali Sheikh ◽  
Umme Salma ◽  
Baohai Zhang ◽  
Jimei Chen ◽  
Jian Zhuang ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Heart Failure ◽  
Brain Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Clinical Management ◽  
Treatment Strategies ◽  
Public Health Problem ◽  
Major Public Health Problem ◽  
Circulating Mirnas ◽  
Heart Failure Patients

Heart failure is a major public health problem especially in the aging population (≥65 years old), affecting nearly 5 million Americans and 15 million European people. Effective management of heart failure (HF) depends on a correct and rapid diagnosis. Presently, BNP (brain natriuretic peptide) or N-terminal pro-brain natriuretic peptide (NT-proBNP) assay is generally accepted by the international community for diagnostic evaluation and risk stratification of patients with HF. However, regardless of its widespread clinical use, BNP is still encumbered by reduced specificity. As a result, diagnosis of heart failure remains challenging. Although significant improvement happened in the clinical management of HF over the last 2 decades, traditional treatments are ultimately ineffective in many patients who progress to advanced HF. Therefore, a novel diagnostic, prognostic biomarker and new therapeutic approach are required for clinical management of HF patients. Circulating miRNAs seem to be the right choice for novel noninvasive biomarkers as well as new treatment strategies for HF. In this review, we briefly discuss the diagnostic, prognostic, and therapeutic role of circulating miRNAs in heart failure patients. We also mentioned our own technique of extraction of RNA and detection of circulating miRNAs from human plasma and oxidative stress associated miRNAs with HF.

scholarly journals Chronic subcutaneous brain natriuretic peptide therapy in asymptomatic systolic heart failure

2016 ◽  
Vol 18 (4) ◽  
pp. 433-441 ◽  
Author(s):  
Paul M. McKie ◽  
John A. Schirger ◽  
Sherry L. Benike ◽  
Lynn K. Harstad ◽  
Joshua P. Slusser ◽  
...  
Keyword(s):  
Heart Failure ◽  
Brain Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Systolic Heart Failure ◽  
Peptide Therapy

Prognostic Usefulness of Anemia and N-Terminal Pro-Brain Natriuretic Peptide in Outpatients With Systolic Heart Failure

2007 ◽  
Vol 100 (10) ◽  
pp. 1571-1576 ◽  
Author(s):  
Morten Schou ◽  
Finn Gustafsson ◽  
Caroline N. Kistorp ◽  
Pernille Corell ◽  
Andreas Kjaer ◽  
...  
Keyword(s):  
Heart Failure ◽  
Brain Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Systolic Heart Failure
Sign in / Sign up

Export Citation Format

Share Document